摘要
目的研究伊立替康联合雷替曲塞在晚期结直肠癌二线化疗中的疗效及安全性。方法我院2010年1月—2012年8月共30例晚期结直肠癌患者一线FOLFOX方案化疗失败后,予伊立替康联合雷替曲塞二线化疗。治疗方案:伊力替康:250～300 mg/m2,静脉滴注1 h/d;雷替曲塞:3 mg/m2,静脉滴注15 min/d;21 d/周期。病情进展或者不能耐受即停止化疗,每2～3个周期评价疗效1次,最多化疗6个周期。观察其疗效、毒副作用及安全性。结果 30例患者均按计划完成治疗。部分缓解5例,疾病稳定10例,疾病进展15例,无完全缓解者,中位无进展生存时间3.8个月;中位总生存时间13.4个月。最常见的毒副作用为中性粒细胞下降和疲倦/食欲下降,发生率分别为73%和70%。最常见的3、4度毒副作用为中性粒细胞下降和腹泻,发生率分别为20%和13%。结论伊立替康联合雷替曲塞在晚期结直肠癌的二线化疗中,有效率较高,毒副作用能够耐受,是一个值得推荐的化疗方案。
Objective To study on the efficacy and safety of irinotecan combined with raltitrexed as second - line chemotherapy for advanced colorectal cancer. Methods Thirty patients with advanced colorectal cancer who failed to first - line chemotherapy with FOLFOX were treated with irinotecan combined with raltitrexed as second - line chemotherapy between January 2010 and August 2012. The treatment protocols： ifinotecan 250 - 300 mg/m2, intravenous infusion of 1 h/d; raltitrexed 3 mg/ m2, intravenous infusion of 15 minutes/d; 21 days as a treatment cycle. The chemotherapy was stopped when the progress of disease or intolerance was observed. The efficacy was evaluated once every 2 -3 cycles, and up to 6 cycles of chemotherapy were conducted. The efficacy, side effects and safety of the treatment were observed. Results All patients successfully completed the treatment plan. There was 0 case of complete recovery, 5 partial recovery, 10 stable disease, and 15 progressive disease. Median progression -free survival was 3.8 months, and median overall survival was 13.4 months. The most common side effects were neutrophil decline and fatigue/appetite decrease with incidence rates of 73% and 70%, respectively. The most common grade 3 and 4 side effects were neutrophil decline and diarrhea with incidence rates of 20% and 13%, respectively. Conclusion Irinotecan combined with raltitrexed as second - line chemotherapy has a high efficacy with acceptable tolerability, therefore is a therapy worth recommending for advanced colorectal cancer.
出处
《中国全科医学》
CAS
CSCD
北大核心
2013年第5期555-557,共3页
Chinese General Practice
关键词
伊立替康
雷替曲塞
晚期结直肠癌
二线化疗
Irinotecan
Raltitrexed
Advanced colorectal cancer
Second-line chemotherapy
